Stifel Financial Corp Increases Holdings in Vericel Co. (NASDAQ:VCEL)

Stifel Financial Corp increased its position in Vericel Co. (NASDAQ:VCEL) by 40.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,073 shares of the biotechnology company’s stock after buying an additional 8,020 shares during the quarter. Stifel Financial Corp owned 0.06% of Vericel worth $1,186,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC raised its stake in shares of Vericel by 4,126.7% during the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 619 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 405 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Vericel by 22.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 322 shares during the period. Meeder Asset Management Inc. bought a new stake in Vericel in the third quarter worth $92,000. Finally, Nisa Investment Advisors LLC boosted its position in Vericel by 9.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 220 shares during the period.

Analyst Ratings Changes

VCEL has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a report on Friday, November 8th. Truist Financial lifted their price target on Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Stephens raised Vericel to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com downgraded shares of Vericel from a “hold” rating to a “sell” rating in a research note on Thursday, December 12th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $60.00 price target on shares of Vericel in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $61.14.

Vericel Stock Up 2.8 %

Shares of Vericel stock opened at $56.50 on Monday. The business has a 50 day moving average of $51.74 and a 200 day moving average of $48.27. Vericel Co. has a 52 week low of $32.31 and a 52 week high of $61.49. The company has a market cap of $2.79 billion, a PE ratio of 941.82 and a beta of 1.71.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The business had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million. On average, research analysts anticipate that Vericel Co. will post 0.13 earnings per share for the current year.

Insider Buying and Selling

In other Vericel news, Director Paul K. Wotton sold 2,600 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $58.72, for a total value of $152,672.00. Following the completion of the transaction, the director now owns 27,402 shares in the company, valued at approximately $1,609,045.44. This represents a 8.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Mark Hopper sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $58.72, for a total transaction of $587,200.00. Following the sale, the insider now owns 58,371 shares in the company, valued at approximately $3,427,545.12. This trade represents a 14.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,266 shares of company stock valued at $2,090,636 over the last three months. Corporate insiders own 5.20% of the company’s stock.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.